Q4FY21 revenues were flat at | 1580 crore, up 0.7% YoY amid continued Covid-19 induced impact on radiopharma segment. Specialty pharma (which comprises Radiopharma) de-grew 23.5% YoY to | 602 crore. Generics remained flat at | 309 crore whereas CDMO segment grew 48% YoY to | 574 crore. Contract research & development grew 10% YoY to | 94 crore. EBITDA margins were down 419 bps YoY at 23.7% amid higher other...